CLAIM AMENDMENTS

1. (currently amended): A method for determining a patient-specific, non-antagonistic ratio of two or more therapeutic agents comprising:

i) providing diseased cells obtained from a patient;

ii) characterizing a molecular phenotype of said diseased cells;

iii) matching the molecular phenotype of said diseased cells with the molecular phenotype of a cultured cell line;

iv) providing at least a first and a second therapeutic agent; and

v) assaying the first therapeutic agent in combination with the second therapeutic agent at various ratios *in vitro* on said cultured cell lines to determine a ratio of said first and second therapeutic agents that exhibits a non-antagonistic biological effect on said cultured cell lines,

whereby said ratio is identified as a patient-specific, non-antagonistic ratio,

wherein said non-antagonistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cultured cells are affected in said *in vitro* assay.

2-4. (canceled).

5. (currently amended): A method of preparing a patient-specific pharmaceutical preparation comprising:

i) providing a first composition comprising a first delivery vehicle, said first delivery vehicle having stably associated therewith a first therapeutic agent;

ii) providing a second composition comprising a second delivery vehicle, said delivery vehicle having stably associated therewith a second therapeutic agent; and

iii) combining said first composition and said second composition in a ratio of first therapeutic agent to second therapeutic agent ~~that provides a non-antagonistic effect to cultured cells that have a molecular phenotype similar or identical to cells harvested from the diseased tissue or blood of said patient~~ determined by the method of claim 1.

6. (original): The method of claim 5, wherein combination of said first and second composition occurs immediately prior to use.

7-9. (canceled)

10. (currently amended): A method of preparing a patient-specific pharmaceutical preparation comprising:

stably associating with a delivery vehicle at least a first and second therapeutic agent in a ratio of the first to second therapeutic agent ~~that provides a non-antagonistic effect to cultured cells that have a molecular phenotype similar or identical to cells harvested from the diseased tissue or blood of the patient~~ determined by the method of claim 1.

11. (original): The method of claim 10, wherein the first therapeutic agent is stably associated with a first delivery vehicle and the second therapeutic agent is stably associated with a second delivery vehicle.

12-14. (canceled)

15. (original): The method of claim 10, wherein the first and second therapeutic agents are co-encapsulated in the same delivery vehicle.

16-21. (canceled)

22. (currently amended): A method of providing a pharmaceutical preparation individualized to a particular patient comprising:

a) obtaining diseased cells from the patient;

b) characterizing the molecular phenotype of said patient's diseased cells;

c) matching the molecular phenotype of said patient's diseased cells with the molecular phenotype of cultured cells;

d) providing at least a first and a second therapeutic agent;

e) conducting an assay *in vitro* on said cultured cells to determine a ratio of at least a first and second therapeutic agent that exhibits a non-antagonistic biological effect on said cultured cells; whereby said ratio is determined as a patient-specific ratio for said individualized treatment; and

f) mixing a first composition comprising a first delivery vehicle associated with said first therapeutic agent with a second composition comprising a second delivery vehicle stably associated with said second therapeutic agent in the patient- specific ratio determined in e), wherein the pharmacokinetics of the delivery vehicles in said first and second compositions are coordinated,

wherein said non-antagonistic effect is exhibited over at least 20% of the concentration range such that 20-80% of the cultured cells are affected in said *in vitro* assay.

23-25. (canceled)